Cardiac Monitoring And Cardiac Rhythm Management Devices Market: CRM Holds 73.6% Share
Heart disease remains one of the largest burdens on healthcare systems worldwide, and the technology used to watch, regulate and protect the heart is evolving quickly. From wearable ECG patches to leadless pacemakers, the cardiac monitoring and cardiac rhythm management (CRM) devices market is moving toward connected, continuous and patient-centric care. Here is what the latest Grand View Research analysis says about where the market is headed.
Market Size & Forecast Comparison
The global cardiac monitoring and cardiac rhythm management devices market was valued at USD 30.0 billion in 2025. It is estimated to reach USD 31.9 billion in 2026 and is projected to climb to USD 49.8 billion by 2033, growing at a CAGR of 6.5% from 2026 to 2033.
The segment and regional picture adds useful contrast. By product, cardiac rhythm management devices lead with a 73.6% share, while cardiac monitoring devices are growing fastest. By end use, hospitals lead with 53.4%, while ambulatory surgery centers are growing fastest. By region, North America leads with 45.6%, while Asia Pacific is growing fastest.
In short, established CRM devices such as pacemakers, ICDs and CRT systems anchor today's revenue, while monitoring devices, outpatient settings and Asia Pacific are set to drive the next wave of growth.
Major Drivers
Rising cardiovascular disease burden. Global age-standardized prevalence of cardiovascular disease is around 7,179 cases per 100,000 people, which means millions of patients need ongoing monitoring and timely intervention. In the U.S., atrial fibrillation affected about five million people in 2024, with projections of more than 12 million by 2030.
Awareness and screening programs. Guidelines from the AHA, ACC, ACCP and HRS encourage routine pulse and ECG screening for AFib in high-risk groups such as older adults. Community initiatives, like free ECG screenings for teenagers that have identified serious conditions such as hypertrophic cardiomyopathy in roughly 1 in 250 participants, are widening the pool of diagnosed patients.
An aging population. Asia Pacific alone is home to about 697 million people aged 60 and above, roughly 60% of the world's older population, a group more susceptible to cardiac conditions.
Technological advancement. Leadless and MRI-compatible pacemakers, next-generation ICDs, and remote monitoring platforms are improving outcomes and device longevity, which supports both new adoption and replacement demand.
Go Deeper! Ask Prism AI about the Global Cardiac Monitoring and Cardiac Rhythm Management Devices Market. Get instant answers to questions related to market sizing, growth drivers and their impact, and more.
Trends
Wearables and remote monitoring go mainstream. Disposable chest-worn biosensors, smartphone-connected event monitors and AI-powered patches now support monitoring windows of up to 30 days outside the hospital. Examples from the past year include LifeSignals' UbiqVue 2AYe Holter System, CB Scientific's MyCardia AT and vTitan's vCardio.
Data connectivity is becoming standard. Devices transmit ECG and vital-sign data over Wi-Fi, Bluetooth or cellular networks to cloud platforms, integrate with EHR systems, and trigger real-time alerts, all within HIPAA, GDPR and regional compliance requirements.
AI-enabled analytics. Cloud-based ECG analysis is cutting review times from days to hours. Philips' ePatch with Cardiologs analytics, rolled out across 14 hospitals in Spain, and OMRON Healthcare's global ECG strategy both point to AI becoming core to diagnosis.
Care shifting to outpatient settings. Ambulatory surgery centers are increasingly performing low-risk pacemaker and loop recorder implants, and the American College of Cardiology launched its CV ASC Registry Suite to track this shift.
Regulatory pathways are evolving. Expedited review programs and digital health frameworks are helping wearable monitors, implantable loop recorders and next-generation rhythm devices reach clinicians faster.
Challenges
High device and procedure costs. Pacemaker implantation can range from USD 10,000 to 50,000, defibrillator implantation from USD 25,000 to 80,000, and CRT devices from USD 35,000 to 45,000. Combined with reimbursement limits and out-of-pocket expenses, this can restrict adoption in cost-sensitive healthcare systems.
Product recalls. A published analysis counted 189 Class I recalls in cardiovascular devices, which erodes confidence among patients and clinicians while raising regulatory scrutiny, operating costs and quality-control requirements.
Lengthy regulatory timelines. Strict FDA and EMA evaluation criteria protect patients but can extend development timelines and approval costs, particularly for emerging players with limited regulatory experience.
Want the full numbers behind this outlook? Download Free Sample Report
Competitive Landscape
The market is innovation-led, and large players actively use partnerships, geographic expansion and M&A to strengthen their positions. Key companies profiled in the report include:
- Stryker
- Medtronic
- Abbott
- Boston Scientific Corporation
- Koninklijke Philips N.V.
- ZOLL Medical Corporation (an Asahi Kasei company)
- GE HealthCare
- MicroPort Scientific Corporation
- NIHON KOHDEN CORPORATION
- Biotronik SE & Co KG
Mature players versus emerging players. Mature leaders such as Medtronic compete on clinically validated devices, long-standing physician trust, regulatory expertise and integrated service infrastructure. Their challenge is agility: legacy systems and long replacement cycles can slow the adoption of disruptive technologies. Emerging players such as MicroPort Scientific focus on AI-enabled, miniaturized and wearable technologies, using hospital and research collaborations to build clinical credibility. Their hurdles are narrower portfolios, smaller clinical datasets and the challenge of scaling production and support.
Recent moves to watch:
- December 2025: Teleflex agreed to acquire BIOTRONIK's Vascular Intervention business for approximately €760 million.
- December 2025: Ventripoint partnered with the Nisga'a Valley Health Authority to bring AI-powered cardiac imaging to remote and Indigenous communities in British Columbia.
- March 2025: MicroPort launched its TEN pacemaker family in China and received CE Mark approval for its SmartView Connect App Mobile for remote monitoring across Europe.
- June 2024: Stryker launched the LIFEPAK 35 monitor/defibrillator for EMS and hospital use.
There are currently no direct substitutes for these systems. Standard ECGs and periodic check-ups cannot match the continuous, high-fidelity monitoring and therapeutic capability of implantable devices, wearable sensors and advanced rhythm management solutions.
The Road Ahead
With North America leading today and Asia Pacific growing fastest, the market is set to expand by nearly USD 20 billion between 2025 and 2033. Companies that combine clinical credibility with connected, AI-driven and patient-friendly design are best placed to capture that growth.
Make informed decisions using comprehensive facility-level intelligence. Sign up here
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- الألعاب
- Gardening
- Health
- الرئيسية
- Literature
- Music
- Networking
- أخرى
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness